ACHIEVE LIFE SCIENCES INC. - COMMON SHARES

Achieve Life Sciences Announces Presentation of Cytisinicline E-Cigarette Cessation (ORCA-V1) Results at Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting

11 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Achieve Life Sciences Announces Participation at Upcoming Investor Conferences

07 Sep 2023 07:00:01 By Nasdaq GlobeNewswire

Achieve Life Sciences Reports Financial Results for Second Quarter 2023 and Provides Corporate Update

14 Aug 2023 15:00:00 By Nasdaq GlobeNewswire

Achieve Life Sciences to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast

01 Aug 2023 07:00:01 By Nasdaq GlobeNewswire

Achieve Life Sciences Announces Presentation at 2023 American Society of Pharmacognosy Annual Meeting

18 Jul 2023 07:00:01 By Nasdaq GlobeNewswire

Achieve Life Sciences Announces Publication of Cytisinicline Phase 3 ORCA-2 Smoking Cessation Trial in Journal of the American Medical Association (JAMA)

11 Jul 2023 10:23:26 By Nasdaq GlobeNewswire

Achieve Life Sciences Announces Participation at Upcoming Investor Conferences

06 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

Achieve Life Sciences Announces Pricing of $16.5 Million Registered Direct Offering

25 May 2023 08:00:00 By Nasdaq GlobeNewswire

Achieve Life Sciences Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical Trial

23 May 2023 05:00:00 By Nasdaq GlobeNewswire

Achieve Life Sciences Announces Refinancing of Outstanding Loan with Silicon Valley Bank

17 May 2023 07:00:01 By Nasdaq GlobeNewswire

Achieve Life Sciences Reports Financial Results for First Quarter 2023 and Provides Corporate Update

09 May 2023 15:05:01 By Nasdaq GlobeNewswire

Achieve Life Sciences to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 9, 2023

26 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

Achieve Life Sciences Announces Positive Phase 2 ORCA-V1 Trial Results Showing Statistically Significant Vaping Cessation Benefit for Participants Treated with Cytisinicline

20 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

Achieve Life Sciences to Present at Life Science Innovation Northwest 2023 Conference

14 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Achieve Life Sciences Announces Refresh to Board of Directors

30 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation

29 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Achieve Life Sciences Announces Granting of New Hire Inducement Award

17 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2022 and Provides Corporate Update

16 Mar 2023 15:05:00 By Nasdaq GlobeNewswire

Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation

08 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Achieve Life Sciences Announces Presentation of the Phase 3 ORCA-2 Trial of Cytisinicline at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting

03 Mar 2023 07:00:00 By Nasdaq GlobeNewswire